Crohns MAP Vaccine

The Crohns MAP Vaccine is an experimental Viral vector vaccine intended to prevent or treat Crohn's disease, by provoking an immune response to one possible causative agent of the disease, Mycobacterium avium subsp. paratuberculosis.^[1][2][3][4] The vaccine is currently about to begin Phase 2 of its development.^[5][6] One of the scientists involved with this research is Thomas Borody, known for his work in developing the 'Triple Therapy' for treating ulcers caused by Helicobacter pylori.^[7]

References

1. Agrawal, Gaurav; Clancy, Annabel; Huynh, Roy; Borody, Thomas (2020-04-09). "Profound remission in Crohn's disease requiring no further treatment for 3–23 years: a case series". Gut Pathogens. 12 (1): 16. doi:10.1186/s13099-020-00355-8. ISSN 1757-4749. PMC 7144342. PMID 32308741.
2. Qasem, Ahmad; Elkamel, Erij; Naser, Saleh A. (November 2020). "Anti-MAP Triple Therapy Supports Immunomodulatory Therapeutic Response in Crohn's Disease through Downregulation of NF-κB Activation in the Absence of MAP Detection". Biomedicines. 8 (11): 513. doi:10.3390/biomedicines8110513. PMC 7698721. PMID 33217961.
3. Balseiro, Ana; Perez, Valentin; Juste, Ramon A. (2019-02-01). "Chronic regional intestinal inflammatory disease: A trans-species slow infection?". Comparative Immunology, Microbiology and Infectious Diseases. 62: 88–100. doi:10.1016/j.cimid.2018.12.001. ISSN 0147-9571. PMID 30711052. S2CID 73449846.
4. Feller, Martin; Huwiler, Karin; Stephan, Roger; Altpeter, Ekkehardt; Shang, Aijing; Furrer, Hansjakob; Pfyffer, Gaby E; Jemmi, Thomas; Baumgartner, Andreas; Egger, Matthias (September 2007). "Mycobacterium avium subspecies paratuberculosis and Crohn's disease: a systematic review and meta-analysis". The Lancet Infectious Diseases. 7 (9): 607–613. doi:10.1016/s1473-3099(07)70211-6. ISSN 1473-3099. PMID 17714674.
5. "Crohn's MAP Vaccine". Crohn's MAP Vaccine. Retrieved 2021-06-19.
6. "The Crohn's Vaccine". Crohn's MAP Vaccine. Retrieved 2021-06-19.
7. "Putting MAP on the Map". Crohn's MAP Vaccine. Retrieved 2021-06-19.